Anthem Blue Cross

Prior authorization requirements for CAR-T Therapy

Anthem Blue Cross will continue to require prior authorization (PA) for chimeric antigen receptor (CAR) T-cell immunotherapy. Currently chimeric antigen receptor (CAR) T-cell immunotherapy and all inpatient stays require PA.

Anthem will continue to require PA for CAR-T therapy regardless of the place of service in which it is given and regardless if it is billed with an unlisted code. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions take precedence over these PA rules and must be considered first when determining coverage. Non-compliance with requirements may result in denied claims.

CAR-T therapy is currently represented by the following codes. However, CAR-T therapy in any form will continue to require a PA.

- Q2040 - Tisagenlecleucel, up to 250 million CAR-positive viable T cells, including leukapheresis and dose preparation procedures, per infusion. [Kymriah]
- Q2041 - Axicabtagene Ciloleucel, up to 200 million Autologous Anti-CD19 CAR T Cells, including leukapheresis and dose preparation procedures, per infusion. (New Code Effective 4/1/18)

Not all PA requirements are listed here. Detailed PA requirements are available to contracted providers by accessing the Provider Self-Service Tool at www.Availity.com. Contracted and non-contracted providers who are unable to access Availity may call our Provider Services at the phone number on the back of the member’s ID card for PA requirements.

70907MUPENMUB 02/20/2018

Anthem Blue Cross is the trade name of Blue Cross of California: Independent licensee of the Blue Cross Association. ® ANTHEM is a registered trademark of Anthem Insurance Companies, Inc. The Blue Cross names and symbols are registered marks of the Blue Cross Association.